earnings
confidence high
sentiment negative
materiality 0.70
Amphastar Q3 net income drops 57% YoY to $17.4M; adjusted EPS $0.93 vs $0.96
Amphastar Pharmaceuticals, Inc.
2025-Q3 EPS reported
$1.52
revenue$536,782,000
- Net revenues of $191.8M, flat YoY vs $191.2M.
- GAAP net income of $17.4M ($0.37 diluted EPS) vs $40.4M ($0.78) in Q3 2024.
- Adjusted non-GAAP net income $44.7M ($0.93 diluted EPS) vs $49.6M ($0.96).
- BAQSIMI revenue grew 14% YoY; FDA approval and launch of iron sucrose injection noted.
- Nine-month 2025 GAAP net income $73.7M ($1.52 EPS) vs $121.6M ($2.32) prior year.